Trials / Completed
CompletedNCT00004827
Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 46 (planned)
- Sponsor
- Retina Foundation of the Southwest · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Evaluate the potential of nutritional docosahexaenoic acid (DHA) supplementation to normalize the level of DHA in red blood cells, and to retard the progression of visual function loss in patients with early stage X-linked retinitis pigmentosa.
Detailed description
PROTOCOL OUTLINE: This is a randomized, parallel, double blind study. Patients receive 2 gel capsules per day of either docosahexaenoic acid (DHA) enriched oil or a placebo oil. Oral DHA supplementation continues daily for 3 years. All patients are followed every 6 months for the 3 year duration of the study. Completion date provided represents the completion date of the grant per OOPD records
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docosahexaenoic acid |
Timeline
- Start date
- 1996-03-01
- Completion
- 2002-06-01
- First posted
- 2000-02-25
- Last updated
- 2015-03-25
Source: ClinicalTrials.gov record NCT00004827. Inclusion in this directory is not an endorsement.